Similar to anaplastic lymphoma kinase-positive (ALK+) NSCLC, EGFR-positive NSCLC is driven by a mutation in the EGFR (epidermal growth factor receptor) gene
Outsmarting Cancer to Profoundly Impact Patients’ Lives
At Takeda Oncology, we aspire to cure cancer with inspiration from patients and innovation from everywhere. We combine rigorous science, innovative commercial operations and the aspiration of transforming cancer from a serious disease to a treatable illness in our efforts to develop transformative medicines. Our demonstrated leadership in the treatment of hematologic cancers and solid tumors combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide.
Cancer is clever, but we know its weaknesses. We’ve discovered new ways to attack vulnerabilities in cancer that affect specific patient populations with significant unmet need.
Patients with limited or ineffective treatment options motivate us every day. We are committed to outsmarting cancer so that more patients can benefit from – and have access to – life-transforming medicines.
Lung cancer is one of the most common cancers and is the leading cause of cancer death worldwide. Even with substantial improvement in cancer screening, diagnosis, and treatment over the past few decades, lung cancer remains the leading cause of cancer death, with approximately 18% of cancer-related deaths worldwide.1 Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all forms of lung cancer.2
Takeda Oncology’s advanced lung cancer research is focused on expanding treatment options for people with anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC (mNSCLC) and epidermal growth factor receptor (EGFR) Exon20 insertion+ mNSCLC. Our ongoing investigation of targeted therapies demonstrates continued progress toward extending and improving the lives of people living with rare forms of NSCLC.
Anaplastic lymphoma kinase-positive (ALK+) NSCLC is a unique type of NSCLC caused by a change in the anaplastic lymphoma kinase (ALK) gene
Hematologic malignancies, or blood cancers, include leukemia, lymphoma, myeloma and myelodysplastic syndromes (MDS). These types of blood cancers can affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system. Each year, more than 1.3 million people worldwide are diagnosed with a blood cancer.
Lymphoma is the most common type of blood cancer and originates from abnormal lymphocytes, a key component of the human immune system.3
Multiple myeloma is a rare blood cancer that arises from the plasma cells, a type of white blood cell which is made in the bone marrow.
Leukemia is a blood cancer that develops in early blood-forming cells. There are four main types of Leukemia.
1 WHO Lung Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=lung. Accessed January 26, 2018. 2 American Cancer Society. What is Lung Cancer? https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Accessed July 29, 2020. 3 Lymphoma Research Foundation. About Lymphoma. https://lymphoma.org/aboutlymphoma/. Accessed January 2021.